Open Access Open Access  Restricted Access Subscription or Fee Access

A brief review on Influenza A virus (H 3 N 2 ) and its effects in human with precondition

Manjari Agrawal, Ansh Aggarwal1, Surya Prakash D.V.

Abstract


A primary cause of human influenza is the viral genus Influenzavirus A, of which H3N2 is a subtype. The virus has undergone various mutations, resulting in the emergence of different strains, affecting pigs, humans, and birds. H3N2 exchanges internal protein-coding genes with other influenza subtypes through reassortment. The H3N2 virus, which is a type of seasonal influenza A virus, is still circulating globally and is causing symptoms very similar to those of the regular flu. In European pigs, the H3N2 virus is a combination of the classical H1N1 avian- like virus and the human H3N2 virus, resulting in a reassortant strain with avian-like HA and NA genes and internal genes from the human H3N2 virus. Antigenic drift occurs frequently in seasonal H3N2 viruses, which are linked to severe sickness in elderly persons. Every year, there are influenza outbreaks that eventually reach pandemic proportions. The treatment and prevention of influenza A virus infection have previously been licenced for two older medications, rimantadine (Flumadine and generic) and amantadine (generic). There is currently no vaccine available for H3N2v infection. Scientists have initiated initial measures in the direction of creating a vaccine; however, the Centers for Disease Control and Prevention (CDC) has stated that there has been no determination to commence large-scale production of a vaccine at this point.

Keywords


Influenza, Virus, Hemagglutinin, Neuraminidase, Treatment.

Full Text:

PDF

References


Poon LL, Song T, Rosenfeld R, Lin X, Rogers MB, Zhou B, et al. Quantifying influenza virus diversity and transmission in humans. Nat Genet. 2016;48:195–200.

Kanegae Y, Sugita S, Endo A, Ishida M, Senya S, Osako K, et al. Evolutionary pattern of the hemagglutinin gene of influenza B viruses isolated in Japan: cocirculating lineages in the same epidemic season. J Virol. 1990;64:2860–5.

Fiore AE, Fry A, Shay D, Gubareva L, Bresee JS, Uyeki TM, et al. Antiviral agents for the treatment and chemoprophylaxis of influenza --- recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR Recomm Rep. 2011;60:1–24.

Carrat F, Vergu E, Ferguson NM, Lemaitre M, Cauchemez S, Leach S, et al. Time lines of infection and disease in human influenza: a review of volunteer challenge studies. Am J Epidemiol. 2008;167:775–85.

To KK, Hung IF, Li IW, Lee KL, Koo CK, Yan WW, et al. Delayed clearance of viral load and marked cytokine activation in severe cases of pandemic H1N1 2009 influenza virus infection. Clin Infect Dis. 2010;50:850–9.

Kallen AJ, Brunkard J, Moore Z, Budge P, Arnold KE, Fosheim G, et al. Staphylococcus aureus community-acquired pneumonia during the 2006 to 2007 influenza season. Ann Emerg Med. 2009;53:358–65.

Kaufman MA, Duke GJ, McGain F, French C, Aboltins C, Lane G, et al. Life-threatening respiratory failure from H1N1 influenza 09 (human swine influenza) Med J Aust. 2009;191:154– 6.

Chartrand C, Leeflang MM, Minion J, Brewer T, Pai M. Accuracy of rapid influenza diagnostic tests: a meta-analysis. Ann Intern Med. 2012;156:500–11.

Kumar S, Henrickson KJ. Update on influenza diagnostics: lessons from the novel H1N1 influenza A pandemic. Clin Microbiol Rev. 2012;25:344–61.

Loeffelholz MJ, Pong DL, Pyles RB, Xiong Y, Miller AL, Bufton KK, et al. Comparison of the FilmArray Respiratory Panel and Prodesse real-time PCR assays for detection of respiratory pathogens. J Clin Microbiol. 2011;49:4083–8.

Kaiser L, Wat C, Mills T, Mahoney P, Ward P, Hayden F. Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations. Arch Intern Med. 2003;163:1667–72.

Ramos EL, Mitcham JL, Koller TD, Bonavia A, Usner DW, Balaratnam G, et al. Efficacy and safety of treatment with an anti-m2e monoclonal antibody in experimental human influenza. J Infect Dis. 2015;211:1038–44.

Jegerlehner A, Schmitz N, Storni T, Bachmann MF. Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J Immunol. 2004;172:5598–605.

Brun-Buisson C, Richard JC, Mercat A, Thiebaut AC, Brochard L, Group R-SAHNvR Early corticosteroids in severe influenza A/H1N1 pneumonia and acute respiratory distress syndrome. Am J Respir Crit Care Med. 2011;183:1200–6.

Glezen WP. Clinical practice. Prevention and treatment of seasonal influenza. N Engl J Med. 2008;359:2579–85.




DOI: https://doi.org/10.37591/rrjomv.v13i1.3218

Refbacks

  • There are currently no refbacks.